Next Article in Journal
Actinomycin V Suppresses Human Non-Small-Cell Lung Carcinoma A549 Cells by Inducing G2/M Phase Arrest and Apoptosis via the p53-Dependent Pathway
Previous Article in Journal
Phlorotannins from Ecklonia cava Attenuates Palmitate-Induced Endoplasmic Reticulum Stress and Leptin Resistance in Hypothalamic Neurons
Open AccessReview

Therapies from Fucoidan: New Developments

Marinova Pty Ltd., 249 Kennedy Drive, Cambridge, Tasmania 7170, Australia
*
Author to whom correspondence should be addressed.
Mar. Drugs 2019, 17(10), 571; https://doi.org/10.3390/md17100571
Received: 30 August 2019 / Revised: 4 October 2019 / Accepted: 4 October 2019 / Published: 9 October 2019
Since our last review in 2015, the study and use of fucoidan has extended in several research areas. Clinical use of fucoidan for the treatment of renal disease has become available and human safety studies have been undertaken on radiolabeled fucoidan for the purpose of imaging thrombi. Fucoidan has been incorporated into an increasing number of commercially available supplements and topical treatments. In addition, new measuring techniques are now available to assess the biologically relevant uptake of fucoidans and to assist in production. Microbiome modulation and anti-pathogenic effects are increasingly promising applications for fucoidans, due to the need for alternative approaches to antibiotic use in the food chain. This review outlines promising new developments in fucoidan research, including potential future therapeutic use.
Keywords: fucoidan; microbiome; analysis; norovirus fucoidan; microbiome; analysis; norovirus
MDPI and ACS Style

Fitton, H.J.; Stringer, D.S.; Park, A.Y.; Karpiniec, S.N. Therapies from Fucoidan: New Developments. Mar. Drugs 2019, 17, 571.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop